SK10092001A3 - Použitie nukleozidu ako liečiva na liečenie odpovede imunitného systému na expozíciu - Google Patents

Použitie nukleozidu ako liečiva na liečenie odpovede imunitného systému na expozíciu Download PDF

Info

Publication number: SK10092001A3
Authority: SK; Slovakia
Prior art keywords: nucleoside; exposure; ribavirin; response; cells
Prior art date: 1999-01-29

Application number

SK1009-2001A

Other languages

English (en)

Slovak (sk)

Inventor

Robert Tam

Original Assignee

Icn Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-29

Filing date

1999-12-20

Publication date

2002-02-05

1999-12-20 Application filed by Icn Pharmaceuticals, Inc. filed Critical Icn Pharmaceuticals, Inc.

2002-02-05 Publication of SK10092001A3 publication Critical patent/SK10092001A3/sk

Links

IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title claims abstract description 23
229960000329 ribavirin Drugs 0.000 title claims abstract description 15
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 title claims abstract description 15
230000028993 immune response Effects 0.000 title description 4
239000002777 nucleoside Substances 0.000 claims abstract description 85
150000003833 nucleoside derivatives Chemical class 0.000 claims abstract description 55
230000000694 effects Effects 0.000 claims abstract description 25
230000004044 response Effects 0.000 claims abstract description 25
206010028980 Neoplasm Diseases 0.000 claims abstract description 19
239000003550 marker Substances 0.000 claims abstract description 13
241000700605 Viruses Species 0.000 claims abstract description 10
239000013566 allergen Substances 0.000 claims abstract description 7
208000035269 cancer or benign tumor Diseases 0.000 claims abstract description 7
241000894006 Bacteria Species 0.000 claims abstract description 4
230000001363 autoimmune Effects 0.000 claims abstract description 3
239000007788 liquid Substances 0.000 claims description 14
238000011282 treatment Methods 0.000 claims description 11
230000000899 immune system response Effects 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 7
239000003147 molecular marker Substances 0.000 claims description 7
230000006472 autoimmune response Effects 0.000 claims description 4
230000002441 reversible effect Effects 0.000 claims description 3
244000005700 microbiome Species 0.000 claims 3
230000002596 correlated effect Effects 0.000 claims 2
238000005562 fading Methods 0.000 claims 1
210000000987 immune system Anatomy 0.000 abstract description 29
125000003835 nucleoside group Chemical group 0.000 abstract description 25
206010061217 Infestation Diseases 0.000 abstract description 5
239000012530 fluid Substances 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 28
201000010099 disease Diseases 0.000 description 21
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
230000014509 gene expression Effects 0.000 description 17
238000000034 method Methods 0.000 description 15
239000000243 solution Substances 0.000 description 10
239000000969 carrier Substances 0.000 description 7
230000000139 costimulatory effect Effects 0.000 description 7
230000036210 malignancy Effects 0.000 description 7
239000000203 mixture Substances 0.000 description 7
208000023275 Autoimmune disease Diseases 0.000 description 6
210000001744 T-lymphocyte Anatomy 0.000 description 6
210000003719 b-lymphocyte Anatomy 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
201000011510 cancer Diseases 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
239000007787 solid Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
206010020751 Hypersensitivity Diseases 0.000 description 5
210000002443 helper t lymphocyte Anatomy 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
239000003826 tablet Substances 0.000 description 5
102000004127 Cytokines Human genes 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
208000036142 Viral infection Diseases 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
230000007815 allergy Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
206010017758 gastric cancer Diseases 0.000 description 4
238000002649 immunization Methods 0.000 description 4
230000003053 immunization Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
201000006417 multiple sclerosis Diseases 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
208000035143 Bacterial infection Diseases 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
108010002350 Interleukin-2 Proteins 0.000 description 3
102000000588 Interleukin-2 Human genes 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
230000024932 T cell mediated immunity Effects 0.000 description 3
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
208000022362 bacterial infectious disease Diseases 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
230000003993 interaction Effects 0.000 description 3
230000001613 neoplastic effect Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
208000030507 AIDS Diseases 0.000 description 2
208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
201000005569 Gout Diseases 0.000 description 2
241000711549 Hepacivirus C Species 0.000 description 2
208000007514 Herpes zoster Diseases 0.000 description 2
241000701806 Human papillomavirus Species 0.000 description 2
108090000174 Interleukin-10 Proteins 0.000 description 2
108090000176 Interleukin-13 Proteins 0.000 description 2
102000003816 Interleukin-13 Human genes 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
241000725643 Respiratory syncytial virus Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
208000005718 Stomach Neoplasms Diseases 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
125000005741 alkyl alkenyl group Chemical group 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
125000003710 aryl alkyl group Chemical group 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
230000037396 body weight Effects 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
210000001175 cerebrospinal fluid Anatomy 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
150000001860 citric acid derivatives Chemical class 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
230000037406 food intake Effects 0.000 description 2
208000010749 gastric carcinoma Diseases 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000008611 intercellular interaction Effects 0.000 description 2
229940047122 interleukins Drugs 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
-1 nucleoside compounds Chemical class 0.000 description 2
239000002674 ointment Substances 0.000 description 2
244000052769 pathogen Species 0.000 description 2
150000002972 pentoses Chemical class 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
201000011549 stomach cancer Diseases 0.000 description 2
201000000498 stomach carcinoma Diseases 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000001541 thymus gland Anatomy 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
238000013519 translation Methods 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
230000003827 upregulation Effects 0.000 description 2
DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
208000026872 Addison Disease Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
208000007984 Female Infertility Diseases 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010018634 Gouty Arthritis Diseases 0.000 description 1
206010061192 Haemorrhagic fever Diseases 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
108010034145 Helminth Proteins Proteins 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
208000001688 Herpes Genitalis Diseases 0.000 description 1
208000000903 Herpes simplex encephalitis Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010021928 Infertility female Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
241000712431 Influenza A virus Species 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
108010002335 Interleukin-9 Proteins 0.000 description 1
208000009388 Job Syndrome Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
239000007993 MOPS buffer Substances 0.000 description 1
208000007466 Male Infertility Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
210000000447 Th1 cell Anatomy 0.000 description 1
210000004241 Th2 cell Anatomy 0.000 description 1
208000024799 Thyroid disease Diseases 0.000 description 1
208000026062 Tissue disease Diseases 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000009824 affinity maturation Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
PYMYPHUHKUWMLA-MROZADKFSA-N aldehydo-L-ribose Chemical compound OC[C@H](O)[C@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-MROZADKFSA-N 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
230000004940 costimulation Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
201000004946 genital herpes Diseases 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
244000000013 helminth Species 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
206010051040 hyper-IgE syndrome Diseases 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
230000017307 interleukin-4 production Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
PGXWDLGWMQIXDT-UHFFFAOYSA-N methylsulfinylmethane;hydrate Chemical compound O.CS(C)=O PGXWDLGWMQIXDT-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
230000004899 motility Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
239000003921 oil Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
244000045947 parasite Species 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
150000003014 phosphoric acid esters Chemical class 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
241000894007 species Species 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
208000021510 thyroid gland disease Diseases 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Molecular Biology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Transplantation (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Neurology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

SK1009-2001A 1999-01-29 1999-12-20 Použitie nukleozidu ako liečiva na liečenie odpovede imunitného systému na expozíciu SK10092001A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US24136799A	1999-01-29	1999-01-29
PCT/US1999/030490 WO2000044388A1 (fr)	1999-01-29	1999-12-20	Modulation de reponse immunitaire par la ribavirine

Publications (1)

Publication Number	Publication Date
SK10092001A3 true SK10092001A3 (sk)	2002-02-05

Family

ID=22910442

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1009-2001A SK10092001A3 (sk)	1999-01-29	1999-12-20	Použitie nukleozidu ako liečiva na liečenie odpovede imunitného systému na expozíciu

Country Status (20)

Country	Link
EP (1)	EP1146883A4 (fr)
JP (1)	JP2002535371A (fr)
KR (1)	KR20020023939A (fr)
CN (1)	CN1334736A (fr)
AU (1)	AU2483300A (fr)
BR (1)	BR9917090A (fr)
CA (1)	CA2357735A1 (fr)
CZ (1)	CZ20012519A3 (fr)
HK (1)	HK1040937A1 (fr)
HR (1)	HRP20010496A2 (fr)
HU (1)	HUP0200027A2 (fr)
IL (1)	IL144130A0 (fr)
MX (1)	MXPA01007211A (fr)
NO (1)	NO20013529L (fr)
PL (1)	PL364699A1 (fr)
RU (1)	RU2211698C2 (fr)
SI (1)	SI20802A (fr)
SK (1)	SK10092001A3 (fr)
WO (1)	WO2000044388A1 (fr)
ZA (1)	ZA200105595B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6680059B2 (en)	2000-08-29	2004-01-20	Tripep Ab	Vaccines containing ribavirin and methods of use thereof
JP5175417B2 (ja)	2000-08-17	2013-04-03	トリペップアクチボラゲット	リバビリンを含むワクチンおよびその使用方法
US7022830B2 (en)	2000-08-17	2006-04-04	Tripep Ab	Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6858590B2 (en)	2000-08-17	2005-02-22	Tripep Ab	Vaccines containing ribavirin and methods of use thereof
US20050182252A1 (en)	2004-02-13	2005-08-18	Reddy K. R.	Novel 2'-C-methyl nucleoside derivatives
CN101410122A (zh) *	2006-03-14	2009-04-15	厚生药业股份有限公司	治疗过敏性疾病的方法及组合物
US8071561B2 (en)	2007-08-16	2011-12-06	Chrontech Pharma Ab	Immunogen platform

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4211771A (en) *	1971-06-01	1980-07-08	Robins Ronald K	Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
EP0038629A1 (fr) *	1980-04-17	1981-10-28	Beecham Group Plc	Dérivés du virazole, procédé pour leur préparation et leur utilisation comme agents antiviraux
BE902199A (fr) *	1984-10-29	1985-07-31	Vira Tek Inc	Procede de traitement medical de maladies virales utilisant le 1-beta-d-ribofurannosyl-1, 2,4-triazole-3-carboxamide.
AU5668886A (en) *	1986-03-27	1987-10-20	Harry Edward Gruber	A method of increasing adenosine excretion
US5030623A (en) *	1986-03-27	1991-07-09	The Regents Of The University Of California	Methods for increasing extracellular adenosine and for stabilizing mast cells
US5405837A (en) *	1993-05-18	1995-04-11	Indiana University Foundation	Method for the treatment of neoplastic disease utilizing tiazofurin and ribavirin
RU2088232C1 (ru) *	1995-02-14	1997-08-27	Государственный научный центр вирусологии и биотехнологии "Вектор"	Ингибитор репродукции вируса марбург
US5767097A (en) *	1996-01-23	1998-06-16	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
PL187439B1 (pl) *	1996-01-23	2004-07-30	Icn Pharmaceuticals	Zastosowanie rybawiryny
ATE238328T1 (de) *	1996-10-16	2003-05-15	Ribapharm Inc	Monozyklische l-nukleoside, analoga und ihre anwendungen

1999
- 1999-12-20 IL IL14413099A patent/IL144130A0/xx unknown
- 1999-12-20 CZ CZ20012519A patent/CZ20012519A3/cs unknown
- 1999-12-20 AU AU24833/00A patent/AU2483300A/en not_active Abandoned
- 1999-12-20 CA CA002357735A patent/CA2357735A1/fr not_active Abandoned
- 1999-12-20 BR BR9917090-6A patent/BR9917090A/pt not_active IP Right Cessation
- 1999-12-20 JP JP2000595690A patent/JP2002535371A/ja not_active Withdrawn
- 1999-12-20 RU RU2001119056/14A patent/RU2211698C2/ru not_active IP Right Cessation
- 1999-12-20 EP EP99968159A patent/EP1146883A4/fr not_active Withdrawn
- 1999-12-20 WO PCT/US1999/030490 patent/WO2000044388A1/fr not_active Ceased
- 1999-12-20 SI SI9920099A patent/SI20802A/sl not_active IP Right Cessation
- 1999-12-20 HK HK02102923.6A patent/HK1040937A1/zh unknown
- 1999-12-20 SK SK1009-2001A patent/SK10092001A3/sk unknown
- 1999-12-20 PL PL99364699A patent/PL364699A1/xx not_active Application Discontinuation
- 1999-12-20 MX MXPA01007211A patent/MXPA01007211A/es unknown
- 1999-12-20 HR HR20010496A patent/HRP20010496A2/hr not_active Application Discontinuation
- 1999-12-20 KR KR1020017009609A patent/KR20020023939A/ko not_active Withdrawn
- 1999-12-20 HU HU0200027A patent/HUP0200027A2/hu unknown
- 1999-12-20 CN CN99815897A patent/CN1334736A/zh active Pending
2001
- 2001-07-06 ZA ZA200105595A patent/ZA200105595B/xx unknown
- 2001-07-17 NO NO20013529A patent/NO20013529L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
SI20802A (sl)	2002-08-31
WO2000044388A1 (fr)	2000-08-03
EP1146883A4 (fr)	2004-11-24
HRP20010496A2 (en)	2003-08-31
CN1334736A (zh)	2002-02-06
MXPA01007211A (es)	2002-05-06
NO20013529D0 (no)	2001-07-17
CA2357735A1 (fr)	2000-08-03
JP2002535371A (ja)	2002-10-22
CZ20012519A3 (cs)	2002-05-15
HUP0200027A2 (en)	2002-04-29
BR9917090A (pt)	2001-10-16
IL144130A0 (en)	2002-05-23
EP1146883A1 (fr)	2001-10-24
KR20020023939A (ko)	2002-03-29
NO20013529L (no)	2001-09-12
HK1040937A1 (zh)	2002-06-28
RU2211698C2 (ru)	2003-09-10
AU2483300A (en)	2000-08-18
ZA200105595B (en)	2002-10-07
PL364699A1 (en)	2004-12-13

Publication	Publication Date	Title
US6455508B1 (en)	2002-09-24	Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
US6815542B2 (en)	2004-11-09	Nucleoside compounds and uses thereof
US6509320B1 (en)	2003-01-21	Purine L-nucleosides, analogs and uses thereof
CN1286258A (zh)	2001-03-07	嘌呤l－核苷、其类似物及其用途
US6423695B1 (en)	2002-07-23	Cytokine related treatments of disease
CN1424913A (zh)	2003-06-18	抗病毒前体药物
JP3393645B2 (ja)	2003-04-07	造血改善のためのオキシプリンヌクレオシド、およびそれらの同族体、ならびにそのアシル誘導体
US20020187945A1 (en)	2002-12-12	Modulation of immune response by ribavirin
SK10092001A3 (sk)	2002-02-05	Použitie nukleozidu ako liečiva na liečenie odpovede imunitného systému na expozíciu
AU732120B2 (en)	2001-04-12	Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
US7056895B2 (en)	2006-06-06	Tirazole nucleoside analogs and methods for using same
EP0998293A1 (fr)	2000-05-10	Traitements lies a la cytokine destines a des affections
US20090176721A1 (en)	2009-07-09	Nucleoside analogs with carboxamidine modified monocyclic base
EP1132393B1 (fr)	2003-04-09	L-Ribavirine et son utilisation
NZ512879A (en)	2003-08-29	Modulation of immune response by Ribavirin
NZ505531A (en)	2001-08-31	7-Propyl-8-oxo-alpha or beta-L-guanine alpha or beta-L-nucleoside
DE29924200U1 (de)	2002-07-18	Modulation einer Immunantwort durch Ribavirin
HK1038365B (en)	2003-08-29	L-ribavirin and uses thereof
EP1329220A1 (fr)	2003-07-23	Traitements liés à la cytokine destinés à des affections
HK1052937A1 (en)	2003-10-03	Cytokine related treatments of disease